Nautilus Biotechnology Inc. Common Stock (NAUT)

FairStock Score: 52/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham investor, I look first for a durable business earning consistent profits. Nautilus is not that yet. It is a development-stage life-sciences company with a proteomics platform, 127 employees, and in the quarter ended June 30, 2026, filed revenue of only $190,000 against a net loss of $14.5 million, or $0.11 per diluted share. That is not a business; it is an expensive research project. The longer record confirms the pattern: FY2023 net loss $63.7 million, FY2024 $70.8 million, FY2025 $59.0 million, with no Lynch category because it has lost money in each of the last four years. Trailing free cash flow is -$51.9 million, a -19.9% FCF yield on the $260.9 million market cap. FairStock calculations at the October 13, 2026 close show P/E -4.56, P/B 1.99, ROE -36.21%, ROCE -20.83%, Piotroski 1/9, and Altman Z 1.99. Debt-to-equity of 0.21 is not alarming, but cash burn and negative returns are. The potential proteome market could be large, but I see no proven competitive moat, no repeat revenue, and no self-funding ability. FairStock's score is 52/100, which is middling at best and likely reflects optionality rather than current value. The profit-growth number of 3.75% is not meaningful against repeated losses. Until Nautilus shows commercial traction, narrowing losses, and a credible path to positive cash flow, it remains speculation, not value. I would want evidence, not hope.

In plain English: Nautilus Biotechnology is an early-stage life-sciences company building a technology to measure proteins. The business looks weak today: it has almost no sales, loses millions each quarter, and its recent filed quarter ended June 30, 2026 showed only $190,000 of revenue against a $14.5 million loss. At the recent $2.05 price and $260.9 million market value, the stock looks expensive relative to today's numbers; its value depends on whether the technology ever becomes a real commercial product.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer